MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 01-31-2026
Autolus Therapeutics plc Long Term Debt Current 2011-2026 | AUTL
Annual Long Term Debt Current Autolus Therapeutics plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 5.05 M | 5.04 M | - | 3.59 M | 2.51 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.05 M | 2.51 M | 4.05 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
10.2 M | $ 18.46 | -0.22 % | $ 2.72 B | USA |
 |
Amgen
AMGN
|
107 M | $ 344.63 | 0.8 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
7.29 M | $ 70.06 | 1.05 % | $ 9.37 B | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Biogen
BIIB
|
86.4 M | $ 179.46 | -0.24 % | $ 26.1 B | USA |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.7 | 3.85 % | $ 17 M | USA |
 |
Adagene
ADAG
|
1.18 M | $ 2.6 | -5.45 % | $ 146 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.14 | -0.95 % | $ 7.55 B |  Australia |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 4.32 | 7.67 % | $ 9.4 B |  Israel |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Compugen Ltd.
CGEN
|
768 K | $ 1.83 | -0.3 % | $ 164 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
4.49 M | $ 1.41 | - | $ 264 M | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.45 M | $ 24.98 | 1.54 % | $ 1.61 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 226.97 | 0.38 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Cellectis S.A.
CLLS
|
8.38 M | $ 3.86 | 1.72 % | $ 116 M |  France |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
39.5 M | $ 109.35 | -3.87 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
414 K | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | Canada |
 |
Corcept Therapeutics Incorporated
CORT
|
829 K | $ 42.1 | 5.59 % | $ 4.35 B | USA |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
402 K | $ 24.77 | 1.93 % | $ 2.93 B | USA |
 |
Cardiff Oncology
CRDF
|
710 K | $ 1.7 | -3.14 % | $ 81 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
224 M | $ 13.96 | 2.01 % | $ 4.31 B | USA |
 |
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
937 K | $ 6.58 | - | $ 1.36 B | USA |